"Novartis' Pluvicto Promising in Delaying Hormone-Sensitive Prostate Cancer"

Novartis Pluvicto shows promise in delaying the progression of hormone-sensitive prostate cancer, significantly outperforming the standard of care in clinical trials ahead of FDA application.

• In clinical trials, Novartis Pluvicto reduced the risk of radiographic progression or death by 28% compared to the standard of care in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.
• The therapy is designed to work alongside the standard of care which includes androgen deprivation therapy, aiming to improve clinical endpoints for patients facing metastasis.
• Data from the phases of clinical research indicate that Pluvicto demonstrates a favorable tolerability profile, enhancing its potential as a treatment option for prostate cancer patients.